Sophia Genetics SA（SOPH）資訊與事件

$8.425

+0.025 (+0.30%)收盤時

SOPH 資訊

2.008-11NASDAQ.COM

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

2.008-05NASDAQ.COM

Biotech Stocks Reach 52-Week Highs Driven by Key Catalysts

8.508-04stocktwits

Sophia Genetics to Develop Cancer Diagnostic Tests

9.508-04seekingalpha

SOPHiA Genetics Q2 Earnings Beat Expectations with Revenue Growth

9.508-04PRnewswire

SOPHiA GENETICS Reports Strong Q2 Results with 27% Revenue Growth

7.507-21NASDAQ.COM

Biotech Stocks Reach 52-Week Highs Driven by Clinical Trials

5.006-22PRnewswire

SOPHiA GENETICS Shareholders Approve All Proposals

5.006-22Newsfilter

SOPHiA GENETICS Shareholders Approve All Proposals

8.506-22NASDAQ.COM

SOPHiA GENETICS Closes $57 Million Public Offering

8.506-19PRnewswire

SOPHiA GENETICS Closes $57.5 Million Public Offering

查看更多資訊

SOPH 事件

8/4 10:30

Company Reports Q2 Revenue of $23.3M, Beating Expectations

Reports Q2 revenue $23.3M, consensus $21.72M. Performance was driven by 60% volume growth in the U.S. and 80% revenue growth in Liquid Biopsy. We delivered an outstanding second quarter, growing revenue 27% year-over-year, while also improving adjusted EBITDA loss by 27%," said CEO Ross Muken.

8/4 10:30

Company Expects Adjusted EBITDA Loss Between $29M and $32M

Consensus $93.38M. The company also expects an adjusted EBITDA loss between $29M and $32M.

6/16 18:00

Sophia Genetics $40M Spot Secondary Re-offered at $4.75

Sophia Genetics $40M Spot Secondary re-offered at $4.75

6/16 16:30

Sophia Genetics Launches Underwritten Public Offering of Ordinary Shares

Sophia Genetics announced the commencement of a proposed underwritten public offering of its ordinary shares. TD Cowen is acting as the lead book-running manager for the offering.

6/4 08:10

Sophia Genetics Signs MOU with MSK for Joint Venture

Sophia Genetics has signed a Memorandum of Understanding, or MOU, with Memorial Sloan Kettering Cancer Center, or MSK, relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK in clinical diagnostics and Sophia Genetics' Ai platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world. Sophia DDM, Sophia Genetics' precision medicine platform, has been used to analyze more than 2.5 million cases since 2014. MSK's in-house NGS program has sequenced more than 150,000 tumor samples since 2014, creating a genomic dataset linked to clinical outcomes, pathology, and radiology records. For patients, the proposed precision medicine hub will act as an incubation studio for discoveries, equipped with a deployment platform to deliver new capabilities to patients worldwide. For biopharma partners, the hub could provide dedicated infrastructure for next-generation companion diagnostics, clinical algorithm development, and evidence generation.

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。